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Background:  The  Advisory  Committee  on  Immunization  Practice  of Thailand  prioritizes  seasonal
inﬂuenza  vaccinations  for populations  who  are  at  highest  risk  for serious  complications  (pregnant  women,
children  6 months–2  years,  persons  ≥65  years,  persons  with  chronic  diseases,  obese  persons),  and  health-
care  personnel  and  poultry  cullers.  The  Thailand  government  purchases  seasonal  inﬂuenza  vaccine  for
these groups.  We  assessed  vaccination  coverage  among  high-risk  groups  in Thailand  from  2010  to 2012.
Methods:  National  records  on  persons  who  received  publicly  purchased  vaccines  from  2010  to 2012  were
analyzed  by  high-risk  category.  Denominator  data  from  multiple  sources  were  compared  to  calculate
coverage.  Vaccine  coverage  was deﬁned  as  the  proportion  of  individuals  in  each  category  who  received
the  vaccine.  Vaccine  wastage  was  deﬁned  as the  proportion  of  publicly  purchased  vaccines  that  were  not
used.
Results:  From  2010  to 2012,  8.18 million  inﬂuenza  vaccines  were  publicly  purchased  (range,  2.37–3.29
million  doses/year),  and  vaccine  purchases  increased  39%  over these  years.  Vaccine  wastage  was 9.5%.
Approximately  5.7 million  (77%)  vaccine  doses  were  administered  to  persons  ≥65  years  and  persons  with
chronic  diseases,  1.4  million  (19%)  to  healthcare  personnel/poultry  cullers,  82,570  (1.1%)  to children  6
months–2  years,  78,885  (1.1%)  to  obese  persons,  26,481  (0.4%)  to  mentally  disabled  persons,  and  17,787
(0.2%)  to pregnant  women.  Between  2010  and  2012,  coverage  increased  among  persons  with  chronic
diseases  (8.6%  versus  14%;  p < 0.01)  and  persons  ≥65  years  (12%,  versus  20%;  p  <  0.01);  however,  coverage
decreased  for mentally  disabled  persons  (6.1%  versus  4.9%;  p  <  0.01),  children  6 months–2  years  (2.3%
versus  0.9%;  p  <  0.01),  pregnant  women  (1.1%  versus  0.9%;  p < 0.01),  and  obese  persons  (0.2%  versus  0.1%;
p <  0.01).
Conclusions: From  2010  to 2012, the  availability  of publicly  purchased  vaccines  increased.  While  cov-
erage  remained  low  for all target  groups,  coverage  was  highest  among  persons  ≥65 years  and  persons
with  chronic  diseases.  Annual  coverage  assessments  are  necessary  to  promote  higher  coverage  among
high-risk  groups  in  Thailand.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. IntroductionInﬂuenza is an acute, vaccine-preventable infection that annu-
lly leads to an estimated 3–5 million severe illness episodes and
pproximately 500,000 deaths globally [1,2]. Inﬂuenza vaccination
∗ Corresponding author. Tel.: +662 5903196.
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is the most effective way to prevent inﬂuenza virus infection. The
World Health Organization (WHO) recommends vaccinating those
most at risk for serious complications, including young children,
the elderly, those with chronic illnesses, and pregnant women  [2].
Vaccination is also recommended for those who  easily transmit
inﬂuenza to high-risk populations (i.e., healthcare personnel) [3,4].
Although inﬂuenza vaccine is not commonly used in most
countries in Southeast Asia, the burden of inﬂuenza in Southeast
Asia is similar to that in other parts of the world where inﬂuenza
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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vig. 1. ACIP-recommended inﬂuenza vaccination target groups in Thailand by year
f recommendation.
accine is now routinely used [5–7]. In Thailand from 2005 to 2008,
he annual incidence of inﬂuenza in young children <5 years was
36 per 100,000 and in persons aged ≥75 was 375 per 100,000 [8].
In Thailand, seasonal vaccination was ﬁrst used in the pub-
ic sector in 2004 to vaccinate healthcare personnel and poultry
ullers in response to avian inﬂuenza A (H5N1), and its use in
andemic preparedness efforts was articulated in Thailand’s 1st
ational Strategy Plan for Pandemic Inﬂuenza Preparedness [9].
urrently, Thailand purchases seasonal inﬂuenza vaccines which
re provided free of charge to four high-risk groups: healthcare per-
onnel, poultry cullers, persons aged ≥65 years, and persons with
hronic diseases [10,11]. Over time Thailand’s Advisory Committee
n Immunization Practice (ACIP) has expanded inﬂuenza vaccine
ecommendations to include eight high-risk populations (Fig. 1)
12,13]. Government purchase of inﬂuenza vaccine increased over
50% between 2009 and 2011 (520,000–2.38 million doses) [14].
ere, we estimate inﬂuenza vaccine uptake and coverage among
igh-risk populations in Thailand’s public sector, and assess vac-
ine wastage. These data can be used to evaluate and inform the
ational vaccination program.
. Methods
We  conducted a retrospective review of seasonal inﬂuenza vac-
ine use in the public sector in Thailand from 2010 to 2012. Since
his study was evaluating a national program, it was exempt from
thical review.
.1. Study setting
Thailand is a middle-income country located in Southeast Asia
hat has a population of 66.0 million (est. 2010) [15]. The Thai GDP
er capita is $5,318USD (est. 2012) [16], and 3.5% of Thailand’s GDP
s spent on health expenditures (est. 2006) [17]. Thailand can be
ivided into ﬁve geographic regions (total est. 2010 population in
arentheses): Metropolitan Bangkok (8.3 million), North (11.6 mil-
ion), Northeast (19.0 million), Central (18.2 million), and South (8.9
illion).
.2. Inﬂuenza vaccine distribution
The Thailand National Health Security Ofﬁce (NHSO) is respon-
ible for providing health promotion activities, prevention services,
reatment, and rehabilitation services to all who are enrolled in the
niversal Coverage Scheme [18]. The Universal Coverage Scheme
rovides health insurance to nearly 75% of the Thai population,
ith the remainder being covered under the Social Security Scheme
nd the Civil Servant Medical Beneﬁts Scheme. Following the 2008
ecommendation by Thailand’s ACIP to vaccinate persons aged ≥65
ears and persons with chronic diseases, NHSO began purchasing
accine for these two high-risk groups. Vaccines purchased were33 (2015) 742–747 743
inactivated, trivalent vaccines, provided to the Ministry of Public
Health in multi-dose formulation (four doses per vial). Vaccines
were distributed to each province based on the estimated num-
ber of persons in these two  target groups (some swapping of
vaccine between provinces may  have occurred). Vaccination was
administered in provincial and district hospitals during a 3-month
campaign (or until vaccine ran out) starting in June of each year.
In Thailand, outpatient clinics in hospitals serve as primary care
centers. Healthcare personnel received no additional incentive
for providing vaccines to the target groups. When administering
vaccine, while healthcare providers prioritized the two target
groups, vaccine was  also administered to the other ﬁve target
groups falling under the ACIP recommendation (pregnant women,
obese persons weighing >100 kg and/or having a body mass
index ≥35 kg/m2, mentally disabled persons, and children aged 6
months–2 years). Healthcare personnel and poultry cullers also
received vaccines free of charge, although these were purchased by
the Department of Disease Control of the Ministry of Public Health.
For the purposes of this study, ‘publicly purchased vaccines’ refer to
those purchased by the Department of Disease Control and NHSO.
2.3. Vaccine database
Each vaccination event was recorded in an electronic health
record that was  developed by NHSO for reimbursement purposes.
After each vaccination, hospital staff entered the vaccine recipient’s
13-digit unique identiﬁcation number, date of birth, date of vacci-
nation, risk group category, province, and type of health insurance
into the electronic health record. Patients not covered by the Uni-
versal Coverage Scheme could still be vaccinated and entered into
this system. National data were compiled by NHSO.
2.4. High-risk group classiﬁcation
In the NHSO electronic database, vaccinees were classiﬁed into
pre-deﬁned risk groups. Each vaccinee was assigned to only one risk
category and some risk categories changed over time. If a vaccinee
fell into >1 risk category, s/he would ﬁrst be classiﬁed in either
the chronic disease or aged ≥65 years groups; for the remaining
risk categories, classiﬁcation was  at the discretion of the health-
care provider. Four risk categories were consistent from 2010 to
2012: obese persons, young children aged 6 months–2 years, men-
tally disabled persons, and pregnant women. Three risk categories
changed between 2010 and 2011–2012: persons aged ≥65 years,
persons with chronic diseases and healthcare personnel/poultry
cullers. Among the persons aged ≥65 years category, in 2010 all
persons aged ≥65 years regardless of health status were included,
whereas in 2011–2012, persons aged ≥65 years with chronic dis-
eases were excluded from the category. In 2010, the persons with
chronic diseases category excluded persons aged ≥65 years with
chronic diseases; however, in 2011–2012 this category included all
persons with chronic diseases regardless of age. Finally, the health-
care personnel/poultry cullers category included all such workers
in 2010, while in 2011–2012 poultry cullers/healthcare personnel
with chronic diseases were excluded from this category.
2.5. Denominator data sources
We used three different data sources to estimate the denomina-
tor; coverage for some risk group categories was estimated using
more than one approach.2.6. National Statistical Ofﬁce data
The National Statistical Ofﬁce reports census data on all
registered nationals [19]. We  used these data to estimate the
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Table 1
Number of inﬂuenza vaccine doses that were publicly purchased and used by year
in  Thailand, 2010–2012.
Year Vaccines purchased Vaccines used, N(%) Vaccines wasted (%)
2010 2,370,678 2,170,813 (92) 8.4
2011 2,515,880 2,259,614 (90) 1044 J.T. Owusu et al. / Va
enominator for persons aged ≥65 years and young children aged
 months–2 years. The data were reported in 1-year age incre-
ents; to estimate the number of infants aged 6 months–1 year,
e calculated 50% of the 1-year age category.
.7. National Health Examination Survey data
The National Health Examination Survey [20] is conducted every
ve years in Thailand to estimate the national prevalence of multi-
le health conditions. This nationally representative survey utilizes
ulti-stage random sampling to identify 30,000 participants for a
ealth interview and examination. The most recent National Heath
xamination Survey was conducted in 2009. The National Health
xamination Survey data were used to estimate the denominator
or young children aged 6 months–2 years, persons aged ≥65 years,
bese persons, and for persons with chronic diseases. Chronic dis-
ases included in the survey were chronic obstructive pulmonary
isorder, asthma, cerebrovascular disease, diabetes mellitus, renal
ailure, and thalassemia.
.8. NHSO inpatient/outpatient data
NHSO maintains databases of all persons who receive inpa-
ient and/or outpatient care from a public hospital in Thailand.
ll patient visits are coded for reimbursement purposes using the
0th Revision of the International Statistical Classiﬁcation of Dis-
ases and Related Health Problems (ICD-10); codes are recorded
t the time of ﬁnal discharge (see Supplemental Table S1 for cate-
ory deﬁnitions). Patients could receive up to two  ﬁnal diagnosis
odes per hospital visit. The data were aggregated, and patients
ith more than one diagnosis were included in each illness cate-
ory. For each ﬁscal year (October–September) that vaccines were
urchased, duplicate diagnoses records for the same patient were
eleted. These data were then used to estimate the denominator for
ersons with chronic diseases, pregnant women, obese persons,
nd mentally disabled persons. Chronic diseases included in the
urvey were heart disease, systemic lupus erythematosus, human
mmunodeﬁciency virus (HIV), and cancer.
.9. Statistical analysis
Demographics characteristics (age, sex, and region of residence)
f vaccinees are presented as number and proportion. All vaccinees
ere kept in their original NHSO-designated categories. However,
ecause some risk group classiﬁcations varied by year we also com-
ined groups to display all who were classiﬁed as persons aged
65 years, persons with chronic diseases, or healthcare person-
el/poultry cullers. Vaccine coverage was calculated among the
ollowing groups for which we had denominator data: (1) persons
ged ≥65 years; (2) persons with chronic diseases; (3) pregnant
omen; (4) obese persons; (5) mentally disabled persons; and (6)
oung children aged 6 months–2 years. In addition, we aggregated
hese data to present a total coverage estimate. We  used the Wil-
on score method to calculate 95% conﬁdence intervals (CI) for each
f our coverage estimates. To graph vaccine coverage by year, we
sed the following denominators for each risk group: National Sta-
istical Ofﬁce census data for young children and persons aged ≥65
ears, National Health Examination Survey and NHSO data for per-
ons with chronic diseases, National Health Examination Survey
ata for obese persons, and NHSO data for pregnant women  and
ersons who were mentally disabled. In the case of calculating cov-
rage for persons with chronic diseases, NHSO data were used as
he denominator source for conditions not included by the National
ealth Examination Survey: heart disease, immunodeﬁciency con-
itions (HIV; systemic lupus erythematosus), and cancer. National
ealth Examination Survey data were used as a denominator for2012 3,294,000 2,976,836 (90) 9.6
Total 8,180,558 7,407,263 (91) 9.5
chronic obstructive pulmonary disease, asthma, cerebrovascular
disease, chronic renal failure, diabetes mellitus, and thalassemia.
Sex differences in coverage within high-risk groups were calculated
using Pearsons’ Chi squared test. Vaccine wastage for each year was
deﬁned as the proportion of vaccines purchased by the public sec-
tor for distribution to high-risk populations that were not used by
these populations. We  used Chi squared test for trend when looking
at changes over the 3-year time period (Epi Info version 7.0, Centers
for Disease Control and Prevention, Atlanta, GA, USA). For all other
analyses, we used PASW version 18.0 (IBM, Armonk, NY, USA). A
two-tailed p value <0.05 was  considered statistically signiﬁcant.
3. Results
From 2010 to 2012, 8.18 million doses of seasonal inﬂuenza
vaccine were purchased by the Royal Thai government (Table 1).
The number of vaccines purchased increased by 39% from 2.37
million doses in 2010 to 3.29 in 2012, and over the 3 years 91%
of all purchased vaccines were administered. From 2010 to 2011,
vaccine wastage increased (8.4% versus 10%), but decreased from
2011 to 2012 (10% versus 9.6%). Across all three years, vaccine
wastage increased (trend p < 0.01), and was  9.5% per year, on
average. Wastage was highest in Bangkok (42% in 2010, 26% in
2011, and 17% in 2012).
3.1. Characteristics of vaccinees
Of all vaccines that were distributed from 2010 to 2012, 29% was
administered in 2010, 31% in 2011, and 40% in 2012 (Table 2). Sixty-
ﬁve percent of the vaccines was  administered to females and the
median age of all vaccinees was 54 years in 2010, 58 years in 2011,
and 59 years in 2012. The median age for persons with chronic dis-
eases was 52 years in 2010 and 57 years in both 2011 and 2012.
Across all three years, 765,984 (19%) of all persons with chronic
diseases who were given a vaccine were aged ≥65 years. Among
persons classiﬁed as persons aged ≥65 years, the median age was 72
years for all three years, and 2,550 (0.2%) were 60–64 years (these
persons were excluded from the coverage estimates below). Among
persons classiﬁed as young children aged 6 months–2 years, 693
(0.2%) were aged ≥3 years, and these persons were also excluded
from coverage estimates. Of the 5 regions in Thailand, the North-
eastern region administered the most vaccines (2,533,674; 34%),
while Bangkok administered the least of the publicly purchased
vaccines (384,560; 5.2%).
3.2. Vaccinees by target groups
From 2010 to 2012, 77% of vaccines were distributed to two
target groups: 3,974,848 (54%) doses were administered to per-
sons with chronic diseases and 1,721,490 (23%) to persons aged
≥65 years persons (Table 3). Additionally, 1,426,686 (19%) vaccines
were administered to healthcare personnel and poultry cullers,
82,570 (1.1%) to young children aged 6 months–2 years, 78,885
(1.1%) to obese persons, 78,516 (1.1%) to persons whose risk
group was  listed as other (not speciﬁed), 26,481 (0.4%) to men-
tally disabled persons, and 17,787 (0.2%) to pregnant women. The
J.T. Owusu et al. / Vaccine 33 (2015) 742–747 745
Table  2
Descriptive characteristics of population receiving inﬂuenza vaccinea in the public sector in Thailand, 2010–2012.
Characteristic Total
(n = 7,407,263)
2010
(n = 2,170,813)
2011
(n = 2,259,614)
2012
(n = 2,976,836)
Sex, male, n (%) 2,581,454 (35) 765,585 (35) 778,543 (35) 1,037,326 (35)
Age,  mean ± SD (median)
All vaccinees
Chronic disease
Persons aged >65 years
Pregnant women
Obese
Mentally disabled
Young children (age 6 months-2 years)
Other
54 ± 19 (57)
53 ± 17 (56)
73 ± 6 (72)
27 ± 8 (26)
41 ± 16 (43)
33 ± 21 (30)
2  ± 5 (1.0)
46 ± 17 (49)
51 ± 20 (54)
47 ± 16 (52)
73 ± 6 (72)
27 ± 7 (26)
41 ± 15 (43)
33 ± 21 (30)
2  ± 6 (1.0)
N/A
55 ± 18 (58)
54 ± 17 (57)
73 ± 6 (72)
27 ± 8 (26)
42 ± 16 (45)
34 ± 21 (31)
1  ± 1 (1.0)
57 ± 4 (40)
56 ± 18 (59)
55 ± 16 (57)
73 ± 6 (72)
27 ± 8 (26)
41 ± 16 (43)
32 ± 21 (28)
1  ± 1 (1.0)
46 ± 17 (42)
Place  of residence, n (%)
Northeastern region
Bangkok
Central region
Southern region
Northern region
2,533,674 (34)
384,560 (5.2)
1,790,625 (24)
978,684 (13)
1,718,443 (23)
728,231 (34)
121,003 (5.6)
520,924 (24)
303,304 (14)
497,004 (23)
774,554 (34)
117,330 (5.2)
55,0518 (24)
293,449 (13)
523,342 (23)
1,030,889 (35)
146,227 (4.9)
719,183 (24)
381,931 (13)
698,097 (23)
a Data missing on 922 (0.01%) for sex, 1,569 (0.02%) for age, and 1,277 (0.02%) for place of residence.
Table 3
Number of inﬂuenza vaccines administered by target group and year, Thailand 2010–2012.
Target group Number of vaccine doses distributed
2010 N (%) 2011 N (%) 2012 N (%) Total N (%)
Chronic disease Aged <65 yearsa Alla 1,006,960 (46)
1,006,960
–
1,324,662 (59)
–
1,324,662
1,643,226 (55)
–
1,643,226
3,974,848 (54)
Age  ≥65 years
Alla
No chronic diseasea
576,035 (27)
576,035
–
454,101 (20)
–
454,101
691,354 (23)
–
691,354
1,721,490 (23)
Chronic disease and age ≥65 years combined 1,582,995 (73) 1,778,763 (79) 2,334,580 (78) 5,696,338 (77)
Healthcare personnel/poultry cullers
Alla
No chronic diseasea
487,953 (23)
487,953
–
424,403 (19)
–
424,403
514,330 (17)
–
514,330
1,426,686 (19)
Young  children (aged 6 months–2 years)a 43,860 (2.0) 21,989 (1.0) 16,721 (0.6) 82,570 (1.1)
Obesea 37,995 (1.8) 21,701 (1.0) 19,189 (0.7) 78,885 (1.1)
Othera – 2 78,514 (2.6) 78,516 (1.1)
Mentally disableda 10,489 (0.5) 7,884 (0.4) 8,108 (0.3) 26,481 (0.4)
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and persons aged ≥65 years (11.5%, 14.3%, and 19.6%, respectively;
p < 0.01; see Table 4 and Fig. 2). Combined vaccine coverage for per-
sons with chronic diseases and persons aged ≥65 years was  9.5% inPregnant womena 7,521 (0.4) 
a Denotes NHSO categorization for the risk groups.
roportion of vaccines administered to persons with chronic dis-
ases increased from 2010 to 2011, and increased in persons aged
65 years from 2011 to 2012. When the two groups were combined
o control for coding changes, there was only a decrease from 2011
o 2012. The proportion of vaccines that were administered to all
ther risk groups decreased from 2010 to 2012 (Table 3).
.3. Inﬂuenza vaccine coverage
Excluding healthcare personnel, poultry cullers, and those who
ere missing a risk group classiﬁcation, overall coverage for the
ombined risk groups was 4.5% in 2010, 4.9% in 2011, and 6.3% in
012 (Fig. 2). For all three years combined, coverage estimates for
ersons with chronic diseases ranged from 12% using the National
eath Examination Survey denominator to 30% using NHSO data.
mong persons aged ≥65 years, coverage ranged from 14% using
ational Heath Examination Survey data to 15% using National
tatistical Ofﬁce data. Coverage estimates among obese persons
anged from 0.1% using National Heath Examination Survey data
o 41% using NHSO data. Coverage estimates ranged from 0.8% to
.9% in pregnant women and 1.5% to 1.6% in young children aged 6
onths–2 years. Coverage among persons with mental disabilities
as 4.9%.4,872 (0.2) 5,394 (0.2) 17,787 (0.2)
From 2010 to 2012, vaccine coverage increased in persons with
chronic diseases (8.6%, 11.2%, and 13.9%, respectively; p < 0.01),Fig. 2. Vaccine coverage by year and target group, Thailand 2010–2012. We do not
include coverage rates for healthcare personnel, poultry cullers, and those who  were
missing a risk group classiﬁcation as we do not have denominator data for these risk
groups.
746 J.T. Owusu et al. / Vaccine 33 (2015) 742–747
Table 4
Vaccine coverage by denominator source and ACIP-recommendation groups, 2010–2012.
Target group National Statistical Ofﬁce data National Health Examination Survey data NHSO inpatient/outpatient data
Coverage (95% conﬁdence interval) Coverage (95% conﬁdence interval) Coverage (95% conﬁdence interval)
2010 2011 2012 2010 2011 2012 2010 2011 2012
Chronic
diseases
– 9.4
(9.3, 9.4)
8.6
(8.6, 8.7)a
12.3
(12.3, 12.4)
11.2
(11.2,
11.2)a
15.2
(15.2, 15.3)
13.9
(13.9,13.9)a
24.4
(24.4, 24.4)
28.1
(28.1, 28.1)
36.1
(36.0, 36.1)
Age  ≥65 years 11.5
(11.4, 11.5)
14.3
(14.2, 14.3)
19.6
(19.6, 19.7)
10.4
(10.4, 10.5)
13.0
(13.0, 13.0)
18.0
(17.9, 18.0)
–
Chronic disease
and age ≥65
years
combined
– 9.8
(9.7, 9.8)
9.5
(9.5, 9.5)a
12.6
(12.5, 12.6)
12.2
(12.1,
12.2)a
16.2
(16.2, 16.2)
15.7
(15.7,
15.7)a
–
Young children
(aged 6
months–2
years)
2.3
(2.3, 2.3)
1.2
(1.2, 1.2)
0.9
(0.9, 0.9)
3.1
(3.0, 3.1)
1.6
(1.5, 1.6)
1.2
(1.2, 1.2)
–
Obese – 0.2
(0.2, 0.2)
0.1
(0.1, 0.1)
0.1
(0.1, 0.1)
72.3
(71.9, 72.6)
29.5
(29.1, 29.8)
29.7
(29.4, 30.1)
Mentally
disabled
–  – 6.1
(6.0, 6.2)
4.0
(3.9, 4.1)
4.9
(4.9, 5.0)
Pregnant 1.0
(1.0, 1.0)b
0.6
(0.6, 0.6)b
– – 1.1
(1.1, 1.1)
0.7
(0.7, 0.7)
0.9
(0.9, 1.0)
Note: Bold indicates denominator sources deemed most reliable to estimate coverage.
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aNHSO inpatient and outpatient data used for denominators missing from Nati
ancer).
b Live births were reported for 2010–2011 only.
010, 12.2% in 2011, and 15.7% in 2012. In all other target groups,
accine coverage decreased between 2010 and 2012: 2.3–0.9% in
oung children aged 6 months–2 years (p < 0.01), 0.2–0.1% in obese
ersons (p < 0.01), 6.1% versus 4.9% in mentally disabled persons
p < 0.01), and 1.1–0.9% in pregnant women (p < 0.01).
Coverage was higher among males than females among young
hildren (male: 1.5%, female: 1.4%, p < 0.01), and mentally disabled
ersons (male: 8.0%, female: 5.8%, p < 0.01). In contrast, coverage
as higher among females than males among obese persons (0.15%
ersus 0.13%, p < 0.01), persons aged ≥65 years (12.9% versus 11.1%,
 < 0.01) and persons with chronic diseases (16.6% versus 9.6%,
 < 0.01).
. Discussion
This is the ﬁrst vaccine coverage evaluation of the inﬂuenza
accine program in Thailand. We found that the number of pub-
icly purchased inﬂuenza vaccines increased 39% from 2010 to
012, yet vaccine wastage also increased and averaged 9.5% annu-
lly. Overall vaccine coverage (excluding healthcare personnel and
oultry cullers for which we had no denominator) was  low (6.3%
n 2012), but was highest (16% in 2012) in the two priority risk
roups, persons with chronic diseases, and persons aged ≥65 years.
dditionally, coverage increased among these groups from 2010 to
012; however, in all other high-risk groups, coverage decreased.
se of different denominators generally had only a small effect on
overage estimates except among obese persons. We  hypothesize
hat few persons are given an admission diagnosis of obesity thus
nderestimating the NHSO denominator.
The distribution of publicly purchased inﬂuenza vaccine to high-
isk groups is a relatively new initiative in Thailand. Although
accination of healthcare personnel and poultry cullers began in
004, it was not until 2008 that Thailand’s NHSO began to purchase
easonal vaccines for persons aged ≥65 years and persons with
hronic diseases. During the 2009 inﬂuenza pandemic, national
nﬂuenza vaccine recommendations were expanded to include
dditional high-risk populations: pregnant women, young childreneath Examination Survey (heart disease, systemic lupus erythematosus, and HIV,
aged 6 months–2 years, obese persons, and mentally disabled per-
sons. However, persons aged ≥65 years and persons with chronic
diseases have remained the priority groups for the inﬂuenza vac-
cine plan of the national health coverage scheme. This explains the
relatively higher coverage in these two  risk groups.
While inﬂuenza vaccination is increasing globally [21], cover-
age among high-risk groups varies between countries. One  study
on vaccine coverage in Germany, Spain, Italy, the United Kingdom,
and France, estimated that during the 2006/2007 inﬂuenza season,
vaccine coverage among persons aged ≥65 years and persons with
chronic diseases ranged from 50% to 70% and 30% to 59%, respec-
tively [22]. In the United States, vaccine coverage was estimated
to be 77% (2012/2013) among children aged 6–23 months, 66%
(2012/2013) among persons aged ≥65 years, and 43% (2011/2012)
among pregnant women  [23,24]. Higher coverage in the United
States and Europe than in Thailand may  reﬂect the maturity of these
programs; for instance, the U.S. ACIP began making inﬂuenza vac-
cine recommendations for high-risk groups in 1984, whereas the
Thai ACIP only began making recommendations in 2004. In South
Korea, a country that in recent years has increased its vaccine pur-
chases, vaccine coverage was estimated at 61% among persons aged
≥65 years and persons with chronic diseases, during the 2004/2005
inﬂuenza season. However, 17 million vaccines were available dur-
ing the 2004/2005 inﬂuenza season, and 33% of the total population
in South Korea received vaccine [25].
A major strength of our evaluation was  our ability to use a
national dataset on vaccine status for all individuals who received
vaccines from public hospitals in Thailand. However, our evalua-
tion also had several limitations. First, vaccine records were not
standardized across all three years which resulted in changes in
risk group classiﬁcation between years making it difﬁcult to assess
temporal changes in coverage. For this reason, the coverage for
combined risk groups is more likely to be accurate. Second, vac-
cines distributed to healthcare personnel and poultry cullers were
pooled in the dataset, making it impossible to ascertain vaccine cov-
erage in healthcare personnel separately, an important risk group.
Third, there was  no ideal denominator data source for persons with
ccine 
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nderlying disease and since some persons may  have more than
ne underlying disease and therefore counted multiple times, we
ay  have underestimated coverage. Fourth, since vaccinees could
nly be classiﬁed in one risk group, we may  have underestimated
overage for some risk groups. Fifth, we did not have access to
nformation on vaccines that went to a person not deﬁned as a
igh-risk group (e.g., military personnel or prisoners) so the esti-
ates of wastage are likely overestimated; despite this, wastage
ates were as expected for multi-dose vials [26]. Finally, we  did
ot include data on privately purchased inﬂuenza vaccine, which
ere about 1.5 times public sales in 2011 [14]. Therefore, we  likely
nderestimate coverage estimates.
As Thailand continues to increase the use of inﬂuenza vac-
ine, these ﬁndings are important to establish baseline coverage
nd highlight programmatic challenges that can be addressed
o increase coverage and reduce wastage. We  hypothesize that
ptimal vaccine use can be achieved through better outreach to
argeted population; however, future studies are needed to inves-
igate acceptance and barriers to inﬂuenza vaccine receipt among
igh-risk groups in Thailand, as well as speciﬁc reasons for wastage,
articularly in Bangkok (e.g., cold chain barriers or suboptimal out-
each). Annual estimates of vaccine coverage will be important to
ssess progress toward program goals. Further, an existing effec-
ive inﬂuenza vaccine program is critical in the event of a pandemic
here rapid vaccine deployment and assessment is paramount. The
esults of this evaluation will inform future evaluation of inﬂuenza
accine coverage and management in Thailand.
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